Data Support Use of Evusheld for Prevention of Symptomatic and Severe COVID-19

A phase 3 trial showed that Evusheld reduced the risk of developing symptomatic COVID-19 in the primary and the 6-month follow-up analysis.

Related Keywords

Colorado ,United States ,Myronj Levin , ,Astrazeneca ,University Of Colorado School Medicine ,Colorado School ,Accessed April ,